Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

[cafead]

via Merck MRK announced that the FDA has accepted its supplemental biologics license application (sBLA), seeking expanded use of its blockbuster PD-L1 inhibitor, Keytruda, in cervical cancer. With the FDA granting priority review to the sBLA, a final decision is expected on Jan 20, 2024.

article source